Sera Prognostics, Inc.
NASDAQ:SERAMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $74.11M
- Beta
- 0.94
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.06M
SERA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Sera Prognostics, Inc.NASDAQ: SERA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $3.03M fell 9.1% year over year, ahead of the -10.5% change in trailing-twelve-month research & development. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.
Context
- Research & development amounted to 16260.5% of revenue in FY2025, down 2869.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -9.1% holds above the trailing-twelve-month pace of -10.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 13.17M USD
- Year-over-year change
- -10.6%
- 4-year CAGR
- +4.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.17M | -10.6% |
| FY2024 | 2024-12-31 | 14.73M | -3.3% |
| FY2023 | 2023-12-31 | 15.23M | +6.9% |
| FY2022 | 2022-12-31 | 14.24M | +29.3% |
| FY2021 | 2021-12-31 | 11.02M | — |
Research & Development vs competitors
How SERA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.5% is the 6th highest of 9, against a peer median of -7.5%.
- Research & development amounts to 22573.7% of revenue for SERA, versus a peer median of 80.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.45M USD | -22.6% | +7.0% | — | |
| LTM Mar 2026 | $32.14M USD | +45.7% | -7.4% | 428.8% | |
| LTM Mar 2026 | $21.18M USD | +82.5% | +30.2% | — | |
| LTM Mar 2026 | CA$19.63M CAD | +4.7% | +15.5% | — | |
| LTM Mar 2026 | $13.34M USD | -7.2% | +1.9% | 38.8% | |
| LTM Mar 2026 | $12.87M USD | -10.5% | -2.6% | 22573.7% | |
| LTM Mar 2026 | $5.46M USD | -7.8% | +691.2% | 106.3% | |
| LTM Mar 2026 | $3.33M USD | -25.7% | -9.5% | 6.0% | |
| LTM Mar 2026 | $319.38K USD | -20.4% | -50.4% | 80.5% | |
| Peer median (excluding SERA) | — | -7.5% | +4.5% | 80.5% | |
Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 82K | 268K | 306K | 77K | 81K |
| Cost of Revenue | 37K | 193K | 210K | 82K | 164K |
| Gross Profit | 45K | 75K | 96K | (5K) | (83K) |
| Gross Margin | 54.9% | 28.0% | 31.4% | -6.5% | -102.5% |
| Research & Development | 11.02M | 14.24M | 15.23M | 14.73M | 13.17M |
| Selling, General & Admin | 24.42M | 31.48M | 24.69M | 21.9M | 23.25M |
| Operating Expenses | 35.44M | 45.73M | 39.92M | 36.63M | 36.42M |
| Depreciation & Amortization | 659K | 756K | 900K | 833K | 940K |
| EBITDA | (33.6M) | (43.37M) | (35.29M) | (32.04M) | (30.98M) |
| EBITDA Margin | -40980.5% | -16182.5% | -11531.7% | -41606.5% | -38245.7% |
| Operating Income | (35.4M) | (45.65M) | (39.82M) | (36.64M) | (36.5M) |
| Operating Margin | -43164.6% | -17034.3% | -13013.4% | -47577.9% | -45066.7% |
| Interest Income | 145K | 456K | 1.64M | 2.75M | 4.59M |
| Interest Expense | 746K | 61K | 55K | 28K | 9K |
| Other Income / Expenses | 386K | 1.47M | 3.58M | 3.74M | 4.58M |
| Income Before Tax | (35.01M) | (44.19M) | (36.24M) | (32.9M) | (31.93M) |
| Pre-Tax Margin | -42693.9% | -16487.3% | -11843.8% | -42724.7% | -39417.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.01M) | (44.19M) | (36.24M) | (32.9M) | (31.93M) |
| Net Margin | -42693.9% | -16487.3% | -11843.8% | -42724.7% | -39417.3% |
| EPS (Basic) | (1.18) | (1.43) | (1.16) | (0.99) | (0.67) |
| EPS (Diluted) | (1.18) | (1.43) | (1.16) | (0.99) | (0.67) |
| Weighted Avg Shares | 30.77M | 30.94M | 31.2M | 33.16M | 47.66M |
| Weighted Avg Shares (Diluted) | 30.77M | 30.94M | 31.2M | 33.16M | 47.66M |
Sera Prognostics, Inc.
NASDAQ:SERA
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.